A Clinical Triad With Fatal Implications: Recrudescent Diffuse Large B-Cell Non-Hodgkin Lymphoma Presenting In The Leukemic Phase With An Elevated Serum Lactic Acid Level And Dysregulation Of The Tp53 Tumor Suppressor Gene - A Case Report And Literature Review

CLINICAL MEDICINE INSIGHTS-BLOOD DISORDERS(2021)

Cited 4|Views0
No score
Abstract
Despite representing 30% to 40% of newly diagnosed cases of adult non-Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL) rarely presents (1) in the leukemic phase (2) with dysregulation of the TP53 tumor suppressor gene and (3) an elevated serum lactic acid level. In this case report and literature review, we highlight this unfortunate triad of poor prognostic features associated with an aggressive and fatal clinical course in a 53-year-old man with recrudescent DLBCL. A leukemic presentation of de novo or relapsed DLBCL is rare and may be related to differential expressions of adhesion molecules on cell surfaces. In addition, TP53 gene mutations are present in approximately 20% to 25% of DLBCL cases and foreshadow worse clinical outcomes. Finally, an elevated serum lactic acid level in DLBCL that is not clearly associated with sepsis syndrome is a poor prognostic factor for survival and manifests as type B lactic acidosis through the Warburg effect.
More
Translated text
Key words
DLBCL, non-Hodgkin lymphoma, leukemic phase, elevated serum lactic acid, TP53 tumor suppressor gene dysregulation
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined